Showing posts with label US. Show all posts
Showing posts with label US. Show all posts

Friday, 10 July 2009

Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience

Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience
A.J. Maxwell
Clinical Radiology (2009) 64, 801-806

Link to Journal

The findings suggests that vacuum-assisted removal is a satisfactory alternative to surgery for the majority of patients, but that particular attention should be paid to ensuring complete lesion removal in view of the relatively high recurrence rate in this series

Friday, 21 March 2008

Experience with ultrasonographically guided vacuum-assisted resection of benign breast tumors

N. Tagaya, A. Nakagawa, Y. Ishikawa, T. Oyama and K. Kubota
Clinical Radiology 63, Issue 4, April 2008, Pages 396-400

Link to journal

Aim - To evaluate the feasibility and safety of vacuum-assisted resection of benign breast tumours using an 8 G handheld device.

Materials and Methods - Over a 2-year period, 22 patients with 26 breast tumours diagnosed as benign using aspiration biopsy cytology were enrolled. The mean patient age was 38 years, and the mean maximal diameter of the tumour was 13 mm. A handheld Aloka SSD 6500 ultrasonography device with a linear-type 7.5 MHz transducer was inserted into the posterior aspect of the tumour with the patient under local anaesthesia, and the tumour was resected under ultrasonographic guidance.

Results - This method was employed successfully in all patients, and the mean operation time was 33 min. Post-procedure complications included subcutaneous bleeding in 12 cases and haematoma in one. The pathological diagnoses were fibroadenoma in 16 cases, mastopathy in six, and tubular adenoma and pseudoangiomatous stromal hyperplasia in two cases each, respectively. Follow-up ultrasonography revealed residual tumours in four cases (15.4%).

Conclusions - Although this method is feasible and safe without severe complications, it is necessary to select appropriate patients, and to obtain informed consent regarding the possibility of recurrence or residual tumour.